MENU
+Compare
ARCT
Stock ticker: NASDAQ
AS OF
Oct 24, 04:59 PM (EDT)
Price
$11.21
Change
-$0.78 (-6.50%)
Capitalization
304.67M

ARCT Arcturus Therapeutics Holdings Forecast, Technical & Fundamental Analysis

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases... Show more

ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ARCT with price predictions
Oct 23, 2025

ARCT sees its Stochastic Oscillator ascending out of oversold territory

On October 14, 2025, the Stochastic Oscillator for ARCT moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 60 instances where the indicator left the oversold zone. In of the 60 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ARCT advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .

ARCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 167 cases where ARCT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 22, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ARCT as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ARCT turned negative on October 22, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

ARCT moved below its 50-day moving average on October 22, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.319) is normal, around the industry mean (24.283). P/E Ratio (0.000) is within average values for comparable stocks, (54.634). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.158). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (2.769) is also within normal values, averaging (351.737).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ARCT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ARCT is expected to report earnings to fall 1,726.47% to $5.53 per share on November 05

Arcturus Therapeutics Holdings ARCT Stock Earnings Reports
Q3'25
Est.
$5.53
Q2'25
Missed
by $3.55
Q1'25
Missed
by $4.11
Q4'24
Missed
by $0.92
Q3'24
Beat
by $0.31
The last earnings report on August 11 showed earnings per share of -34 cents, missing the estimate of $3.21. With 3.84M shares outstanding, the current market capitalization sits at 304.67M.
A.I. Advisor
published General Information

General Information

a developer of technology and therapeutics for rare diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
10628 Science Center Drive
Phone
+1 858 900-2660
Employees
180
Web
https://www.arcturusrx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GVFF6.65N/A
N/A
Greenville Federal Financial Corp.
TKOMF39.47N/A
N/A
Tokio Marine Holdings, Inc.
THNPF40.93N/A
N/A
Technip Energies NV
IRCDF1.37N/A
N/A
Intercede Group PLC
SNWGF8.61-0.12
-1.33%
SNOWLINE GOLD CORP

ARCT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with AXON. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+3.99%
AXON - ARCT
49%
Loosely correlated
+2.18%
LRMR - ARCT
47%
Loosely correlated
+0.51%
RXRX - ARCT
46%
Loosely correlated
-0.35%
MRNA - ARCT
45%
Loosely correlated
-2.23%
IDYA - ARCT
45%
Loosely correlated
-0.77%
More